<DOC>
	<DOC>NCT00961025</DOC>
	<brief_summary>This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic parameters of DA-1229 as well as safety profile.</brief_summary>
	<brief_title>A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>2045 years healthy male subjects Body weight :5090kg, BMI between 18.525 Blood glucose level of 70110mg/dL on the FPG test have a family history of diabetes Serum AST(SGOT), ALT(SGPT)&gt;1.25 times upper limit of normal Creatinine clearance rate&lt;80mL/min show SBP =&lt;100mmHg or &gt;=150mmHg, or DBP=&lt;65mmHg or &gt;=95mmHg, or tachycardia (PR&gt;=100times/min) have a history of drug abuse or show positive for drug abuse or cotinine at urine screening smokers can not digest highfat or highcalorie food(applicable only for the 10mg dose group subjects</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>